

P1188

Poster Session IV

Molecular detection of bacterial resistance

VALIDATION OF A NEW DNA EXTRACTION METHOD FROM AGAR OR LIQUID SWABS FOR MOLECULAR DETECTION OF MRSA, VRE AND KPC UTILIZING THE NANOCHIP® MICROARRAY TECHNOLOGY

Z. Greenberg¹, V. Hurgin¹, R. Sabban-Amin¹

¹Research & Development, Savyon Diagnostics Ltd., Ashdod, Israel

Objectives. Methicillin-resistant *Staphylococcus aureus* (MRSA), Vancomycin-Resistant *Enterococci* (VRE) and *Klebsiella pneumoniae* carbapenemase (KPC) colonization in hospital admitted patients is the leading cause for Hospital Acquired Infections (HAI). It is now evident that HAI can be widely prevented through screening of patients before or during hospital admission and proper patient isolation and management. Savyon Diagnostics has recently finalized the development of a novel molecular-based diagnostic screening test for simultaneous detection of MRSA, VRE and KPC directly from a variety of swab sample types. The test utilizes Savyon's proprietary NanoChip®XL molecular electronic microarray system. The aim of this work is to demonstrate the compatibility of different swabs (amies agar and liquid swabs, Copan, Italy) with our PCR - NanoCHIP® technology for screening large number of samples for simultaneous detection of MRSA, VRE and KPC in variety of clinical samples.

Methods. After routine diagnostic procedure positive amies agar gel as well as liquid (eSwab) medium transport swabs were kept at -20°C. A new protocol was developed in order to allow fast and easy DNA extraction from clinical samples. Pathogen and antibiotic resistance specific genes were amplified through multiplex PCR and subjected to the NanoCHIP® system. The generated amplicons were electronically addressed to discrete loci on the NanoCHIP® cartridge, pre-activated with specific capture oligonucleotides. Detection was achieved through specific fluorescent reporter oligonucleotides. The output analysis of each sample was compared to the characterization of the respective original swab sample, as characterized by real-time PCR in various laboratories.

Results. The novel extraction protocol demonstrated a full compatibility with the downstream PCR-NanoCHIP® technology. The results were in complete accordance with the characterizations of the tested samples in terms of clinical sensitivity and specificity.

Conclusions. The NanoCHIP® has proven to be a useful platform for medium-high throughput screening of MRSA, VRE and KPC colonization, offering reliable diagnosis in various types of swab samples. The newly developed protocol improves the laboratory workflow, minimizes hands-on time and consequently turnaround time, simplifies the pre-PCR DNA extraction procedure, and overall reduces costs.